Results 121 to 130 of about 180,829 (383)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Cell Death and Disease, 2020
Loss of CD20 is a major obstacle for the retreatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL) with Rituximab-associated regimens. Histone deacetylation causes gene silencing and inhibits CD20 expression. Chidamide is a novel inhibitor
Xuwen Guan, Hua-qing Wang, Wei-Wei Ban, Zhi Chang, Haiyun Chen, L. Jia, Feng-Ting Liu   +6 more
semanticscholar   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Algebraic approach to slice monogenic functions [PDF]

, 2014
In recent years, the study of slice monogenic functions has attracted more and more attention in the literature. In this paper, an extension of the well-known Dirac operator is defined which allows to establish the Lie superalgebra structure behind the ...
Cnudde, Lander, De Bie, Hendrik, Ren, Guangbin   +2 more
core   +2 more sources

Pathogenic Role of FGFR3 Autoantibodies in Small Fiber Neuropathy

Advanced Science, EarlyView.
Autoantibodies against fibroblast growth factor receptor 3 (FGFR3) are identified as pathogenic drivers of pain in small fiber neuropathy. By binding to sensory neurons in dorsal root ganglia, FGFR3 autoantibodies activate MAPK signaling and induce hyperexcitability and mechanical hypersensitivity, establishing FGFR3 autoantibodies as a therapeutic ...
Lyuba Y. Salih, Nicolas L.A. Dumaire, Clémence Gieré, Erin Vest, Haya Alkhateeb, Christian P. Moritz, Yannick Tholance, Jean‐Philippe Camdessanché, Jean‐Christophe Antoine, Jérôme Honnorat, Jafar Kafaie, Liberty François‐Moutal, Aubin Moutal   +12 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

CD20 antibody primes B lymphocytes for type I interferon production. [PDF]

PLoS ONE, 2013
CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases.
Dongsheng Xu, Andrew Staedman, Luwen Zhang   +2 more
doaj   +1 more source

Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action [PDF]

, 2021
Wenyan Cai, Jianbo Dong, Sachith Gallolu Kankanamalage, Allison Titong, Jiadong Shi, Zhejun Jia, Bo Wang, Cai Huang, Jing Zhang, Jun Lin, Steven Z. Kan, Shuhua Han, Joe Zhou, Yue Liu   +13 more
openalex   +1 more source

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

Brain Science, 2020
Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder.
Despoina Florou, M. Katsara, J. Feehan, E. Dardiotis, V. Apostolopoulos   +4 more
semanticscholar   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?

Annals of Medical Science and Research
Introduction: Rituximab (RTX), initially approved for various blood cancers, is additionally used for the management of primary central nervous system (CNS) demyelinating disorders.
Sayan Chatterjee, Peyalee Sarkar, Mitali Chatterjee, Biman Kanti Ray   +3 more
doaj   +1 more source